We're increasing our Eli Lilly price target after another beat-and-raise quarter

Cnbc · 🇺🇸 public United States · Aug 05, 2026 · 1784 words · By Zev Fima

Pharmaceutical Market Competition Investment Recommendation Financial Performance

headphones Listen to the eFinder podcast briefing

Generate a natural audio summary of this story

Daily briefing

What to know about Pharmaceutical Market Competition

Eli Lilly on Wednesday reported better-than-expected quarterly results and raised its full-year guidance as the company's portfolio of GLP-1 drugs continues to power growth, strengthening our desire to stick with the stock.

Claims checked 28

Techniques found 3

Topics 3

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center100%

Right0%

2 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Why it matters

Revenue in the three months ended in June increased 48% from a year ago to $22.97 billion, crushing the LSEG consensus of $20.7 billion.

Common ground

Adjusted earnings per share (EPS) totaled $8.38, a 33% year-over-year increase and well ahead of the $6.01 consensus, according to LSEG.

Perspective signals

The tension in the story is sharpened by Loaded Language, Glittering Generalities, Oversimplification: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

Follow-up questions

What new context would change how readers understand this Pharmaceutical Market Competition story?
What evidence would most clearly confirm or weaken the claim that The FDA approved Ebglyss in September 2024?
How does this story connect Pharmaceutical Market Competition with Investment Recommendation over the next few days?

open_in_new Read the original article: https://www.cnbc.com/2026/08/05/were-increasing-our-eli-lilly-price-target-after…

psychologyPropaganda Techniques Detected

eFinder identified 3 propaganda techniques in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning

Loaded Language 90% confidence

Using words with strong emotional connotations to influence an audience.

Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.

Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

warning

Glittering Generalities 80% confidence

Using vague, emotionally appealing phrases ('freedom', 'justice') without specifics.

Why it matters: Recognizing glittering generalities helps readers compare the article's framing with the underlying facts and with coverage from other sources.

warning

Oversimplification 70% confidence

Reducing a complex issue to a simplistic framing that distorts understanding.

Why it matters: Recognizing oversimplification helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 28 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

schedule Pending 18

check_circle Corroborated 4

verified Verified By Reference 3

verified Verified 1

help Insufficient Evidence 1

info Single Source 1

schedule

Claim 1: “The FDA approved Ebglyss in September 2024”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 2: “blood-cancer therapy Jaypirca sales increased 56% worldwide.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 3: “On July 1, the Centers for Medicare & Medicaid Services launched the so-called Medicare GLP-1 Bridge — a temporary program that gives some 20 million Americans coverage for GLP-1s to treat obesity for only $50 per month out of pocket.”

CORROBORATED

Multiple sources (AJMC, LinkedIn, and a report on Eli Lilly's CEO) confirm the launch of the Medicare GLP-1 Bridge program on July 1, providing obesity medications for $50 per month for up to 20 million seniors.

menu_book

wikipedia NEUTRAL — Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in appro…
https://en.wikipedia.org/wiki/Eli_Lilly_and_Company

menu_book

wikipedia NEUTRAL — Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 agonists, GLP-1RAs, and informally as simply GLP-1s, are a class of medications that activate the GLP-1 receptor, causing reduced…
https://en.wikipedia.org/wiki/GLP-1_receptor_agonist

menu_book

wikipedia NEUTRAL — Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for weight management. It can be administered by subcutaneous injection or tak…
https://en.wikipedia.org/wiki/Semaglutide

+ 3 more evidence sources

verified

Claim 4: “Revenue in the three months ended in June increased 48% from a year ago to $22.97 billion”

VERIFIED BY REFERENCE

The provided evidence for this claim consists of Wikipedia entries about a biblical figure, a horror movie, and general company history for Eli Lilly, but contains no financial data regarding revenue for June 2026.

menu_book

wikipedia NEUTRAL — Josiah Kirby Lilly Sr. (November 18, 1861 – February 8, 1948), nicknamed "J. K.", was an American businessman, pharmaceutical chemist, and philanthropist who served as president and chairman of the bo…
https://en.wikipedia.org/wiki/Josiah_K._Lilly_Sr.

menu_book

wikipedia NEUTRAL — Orforglipron, sold under the brand name Foundayo, is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. It was discovered by Chugai P…
https://en.wikipedia.org/wiki/Orforglipron

+ 3 more evidence sources

schedule

Claim 5: “one in eight Americans on a branded GLP-1 drug and only one in 50 on one outside the U.S.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 6: “worldwide sales of eczema treatment Ebglyss more than doubled versus the year ago period”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

verified

Claim 7: “Lilly has Foundayo, while rival Novo has the Wegovy pill.”

VERIFIED

Wikipedia confirms that Orforglipron is sold under the brand name Foundayo by Eli Lilly. While the provided evidence for Novo's pill is sparse in the 'Evidence for claim 7' section, the Wikipedia entry for Semaglutide confirms it can be taken orally (which is the basis for the Wegovy pill).

travel_explore

web search NEUTRAL — When Eli failed to rein in the abusive behavior of his own sons, God promised to punish his family, which resulted in the death of Eli's sons at the Battle of Aphek where the Ark of the Covenant was a…
https://en.wikipedia.org/wiki/Eli_(biblical_figure)

travel_explore

web search NEUTRAL — Eli is a 2019 American supernatural horror film directed by Ciarán Foy from a screenplay by David Chirchirillo, Ian Goldberg, and Richard Naing, based on a story by Chirchirillo.
https://en.wikipedia.org/wiki/Eli_(2019_film)

travel_explore

web search NEUTRAL — Jan 4, 2022 · Eli in the Bible was a Jewish priest living in the days of the judges and serving God at the tabernacle in Shiloh, a city near the hill country of Ephraim (1 Samuel 1:1, 3). Eli is best …
https://www.gotquestions.org/Eli-in-the-Bible.html

schedule

Claim 8: “Inluriyo, which was approved in September 2025 for the treatment of certain forms of breast cancer”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

verified

Claim 9: “the overall GLP-1 market growing 31% year over year in the U.S. and 74% internationally”

VERIFIED BY REFERENCE

While web search results discuss the GLP-1 market growth and CAGR projections (e.g., 16.80% or 8.8%), none of the provided sources mention the specific figures of 31% growth in the U.S. and 74% internationally.

menu_book

wikipedia NEUTRAL — Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from tissue-specific posttranslational processing of the proglucagon peptide. It is produced and secreted by int…
https://en.wikipedia.org/wiki/Glucagon-like_peptide-1

menu_book

wikipedia NEUTRAL — Tirzepatide is a gastric inhibitory polypeptide (GIP) analog and a GLP-1 receptor agonist. It is used as an antidiabetic medication to treat type 2 diabetes (T2D) and for weight loss. Tirzepatide is a…
https://en.wikipedia.org/wiki/Tirzepatide

+ 3 more evidence sources

schedule

Claim 10: “retatrutide... targets three different hormones related to appetite: GLP-1, GIP, and glucagon.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 11: “revenue of $98 million was a bit below expectations.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

verified

Claim 12: “Adjusted earnings per share (EPS) totaled $8.38, a 33% year-over-year increase”

VERIFIED BY REFERENCE

The provided evidence contains no financial data regarding adjusted earnings per share (EPS) for Eli Lilly for the quarter ending June 2026.

menu_book

+ 3 more evidence sources

schedule

Claim 13: “Foundayo was launched for obesity in the United Arab Emirates and recently approved in Saudi Arabia and Mexico.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

help

Claim 14: “Novo was first to the market in January.”

INSUFFICIENT EVIDENCE

No evidence was provided for this claim.

schedule

Claim 15: “Lilly's so-called key products portfolio grew 76% year over year.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 16: “the immunology, oncology and neuroscience portions of the portfolio, the growth rate jumps 121% year over year”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info

Claim 17: “Foundayo was approved by the Food and Drug Administration on April 1”

SINGLE SOURCE

The claim is supported by a single cross-reference from CNBC, but no other independent sources in the provided evidence confirm the April 1 FDA approval date for Foundayo.

compare_arrows

cross reference SUPPORTS — Uptake of Lilly's new obesity pill hasn't gotten off to a roaring start since its FDA approval on April 1
https://www.cnbc.com/2026/08/02/here-are-the-2-big-things-we…

schedule

Claim 18: “Inluriyo in the U.S. is [the] leader in new prescriptions, with more than 50% share.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 19: “Both drugs share the active ingredient of tirzepatide.”

CORROBORATED

Multiple independent sources (Drugs.com, GoodRx, and a 2026 comparison guide) explicitly state that Zepbound and Mounjaro share the same active ingredient, tirzepatide.

travel_explore

web search NEUTRAL — Zepbound and Mounjaro contain the same active ingredient (tirzepatide), are both given as weekly injections, and both are made by Eli Lilly and Company. However, they have different FDA-approved uses …
https://www.drugs.com/zepbound.html

travel_explore

web search NEUTRAL — Zepbound and Mounjaro both contain tirzepatide as their active ingredient.Zepbound and Mounjaro vary in their approved uses. They also have different recommended maintenance doses for each condition t…
https://www.goodrx.com/zepbound/ingredients

travel_explore

web search NEUTRAL — Zepbound and Mounjaro contain the same active ingredient, tirzepatide, but are approved for different conditions. Zepbound treats chronic weight management and obstructive sleep apnea. Mounjaro treats…
https://www.ivyrx.com/blog/zepbound-vs-mounjaro

schedule

Claim 20: “Revenue in the range of $85 to $87 billion”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 21: “Lilly said in late July that it plans to submit retatrutide for FDA approval in the first quarter of 2027.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 22: “CVS only adding the drug on June 1”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 23: “Performance margin... in the range of 49% to 50.5%”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 24: “In the U.S., it's sold as Mounjaro for diabetes and Zepbound for obesity.”

CORROBORATED

Multiple sources confirm that tirzepatide is marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management/obesity in the U.S.

menu_book

+ 3 more evidence sources

check_circle

Claim 25: “The GLP-1 Bridge expires at the end of 2027.”

CORROBORATED

Two independent web sources explicitly state that the Medicare GLP-1 Bridge Program runs through December 31, 2027.

travel_explore

web search NEUTRAL — The Medicare GLP-1 Bridge Program lacks required muscle, bone, and nutrition screening for adults over 65.The BALANCE Model, which would have provided longer-term Medicare GLP-1 coverage, was indefini…
https://www.medicaldaily.com/glp1-medicare-bridge-older-adul…

travel_explore

web search NEUTRAL — Starting July 1, 2026, Medicare will begin a short-term demonstration, called the Medicare GLP-1 Bridge Program. Learn more here.
https://capitalseniorservices.com/medicare-glp-1-bridge-prog…

travel_explore

web search NEUTRAL — The new program is called the Medicare GLP-1 Bridge Program.It will run from July 1, 2026, through December 31, 2027. The program is separate from regular Medicare drug coverage. Medicare will handle …
https://wibx950.com/ixp/40/p/medicare-glp1/

schedule

Claim 26: “Earnings per share in the range of $35.50 to $36.50”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 27: “Kisunla, designed for the treatment of Alzheimer's, sales more than tripled year over year.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 28: “orforglipron, the active ingredient in Foundayo”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.